The present invention relates to compounds of formula (I) wherein R is hydrogen halogen cyano lower alkyl lower alkyl substituted by halogen lower alkoxy lower alkoxy substituted by halogen or C(O)NH or is phenyl optionally substituted by halogen cyano or lower alkoxy substituted by halogen or is 2 2 difluorobenzo d 1 3 dioxol 5 yl or is 6 (trifluoromethyl)pyrazin 2 yl or 5 (trifluoromethyl)pyrazin 2 yl or is 6 (trifluoromethyl)pyrimidin 4 yl or is 6 (trifluoromethyl)pyridin 3 yl or is 5 cyanopyrazin 2 yl or is 2 (trifluoromethyl)pyrimidin 4 yl n is 1 or 2 R is halogen lower alkyl or cyano and R is hydrogen or R is hydrogen and R3 is halogen lower alkyl or cyano X is a bond NR CHNH or CHR R is hydrogen or lower alkyl Z is a bond CH or O Ar is phenyl or is heteroaryl selected from the group consisting of 1H indazole 3yl pyridine 2 yl pyridine 3 yl pyridine 4 yl pyrimidine 5 yl lH pyrazole 3 yl 1H pyrazole 4 yl or lH pyrazole 5 yl or to a pharmaceutically suitable acid addition salt thereof which may be used for the treatment of depression anxiety disorders bipolar disorder attention deficit hyperactivity disorder (ADHD) stress related disorders psychotic disorders schizophrenia neurological diseases Parkinson s disease neurodegenerative disorders Alzheimer s disease epilepsy migraine hypertension substance abuse metabolic disorders eating disorders diabetes diabetic complications obesity dyslipidemia disorders of energy consumption and assimilation disorders and malfunction of body temperature homeostasis disorders of sleep and circadian rhythm and cardiovascular disorders.
